Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
SH1573
/
Nanjing Sanhome Pharma
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
SH1573
/
Nanjing Sanhome Pharma
Preclinical, Journal:
Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China.
(Pubmed Central) - Jul 6, 2021
This research successfully promoted the approval of SH1573 for clinical trials (CTR20200247). All experiments demonstrated that, as a potential drug against mIDH2 R140Q acute myeloid leukaemia, SH1573 was effective and safe.
||
||||||||
SH1573
/
Nanjing Sanhome Pharma
New P1 trial:
A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia
(clinicaltrials.gov) - Mar 19, 2021
P1
, N=41, Recruiting,
Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.